SOCIETY: AGA

Presentations:

TREATMENT WITH THE HISTAMINE 1 RECEPTOR ANTAGONIST EBASTINE FOR NON-CONSTIPATED IRRITABLE BOWEL SYNDROME: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL

IS A SIMPLIFIED LOW FODMAP RESTRICTION PHASE POSSIBLE? RESULTS FROM A MULTI-CENTER, DOUBLE-BLIND, PILOT-FEASIBILITY, RANDOMIZED CONTROLLED TRIAL

DIFFERENCES IN DIETARY INTAKE PATTERNS CONTRIBUTE TO VARIATIONS IN THE WORLDWIDE PREVLANECE OF ROME IV IRRITABLE BOWEL SYNDROME

PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PROOF OF CONCEPT STUDY OF EFFICACY OF RIFAMYCIN SV-MMX® 600 MG ADMINISTERED THREE OR TWO TIMES DAILY TO PATIENTS WITH DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME (IBS-D)

EFFICACY OF A NOVEL, DISCRIMATORY P-VALUE BASED, IGG ASSAY-GUIDED ELIMINATION DIET BY IBS SUBTYPE: RESULTS FROM A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, SHAM-CONTROLLED STUDY

APP-DELIVERED GUT-DIRECTED HYPNOTHERAPY IS SUPERIOR TO PSYCHOEDUCATION IN REDUCING SYMPTOMS ASSOCIATED WITH IRRITABLE BOWEL SYNDROME: A RANDOMISED CONTROL TRIAL

Lukas Michaja Balsiger

Appearances